Nuclear Magnetic Resonance Metabolomics Biomarkers for Identifying High Risk Patients with Extranodal Extension in Oral Squamous Cell Carcinoma
Overview
Authors
Affiliations
Extranodal extension (ENE) is an independent adverse prognostic factor in oral squamous cell carcinoma (OSCC), and is difficult to identify preoperatively. We aimed to discover biomarkers for high risk patients with ENE. Tandem tissue, plasma, and urine samples of 110 patients with OSCC were investigated through 600-MHz nuclear magnetic resonance (NMR) metabolomics analysis. We found that the levels of creatine, creatine phosphate, glycine, and tyramine in plasma significantly decreased in stage IV ENE positive OSCC compared with stage IV ENE negative OSCC. To understand the underlying mechanism behind the alteration of plasma metabolites, our tissue analysis revealed that the carnitine level significantly increased in tumors but significantly decreased in the adjacent normal tissue in advanced stage OSCC, in addition to decreased levels of alanine and pyruvate in tumor tissues. The global metabolomics analysis on tumor tissues also showed that stage IV tumors with an ENE positive status demonstrated higher levels of aspartate, butyrate, carnitine, glutamate, glutathione, glycine, glycolate, guanosine, and sucrose but lower levels of alanine, choline, glucose, isoleucine, lactate, leucine, myo-inositol, O-acetylcholine, oxypurinol, phenylalanine, pyruvate, succinate, tyrosine, valine, and xanthine than tumors with an ENE negative status. We concluded that metabolomics alterations in tumor tissues correspond to an increase in the tumor stage and are detectable in plasma samples. Metabolomic alterations of OSCC can serve as potential diagnostic markers and predictors of ENE in patients with stage IV OSCC.
Intratumoral Microbiome: Foe or Friend in Reshaping the Tumor Microenvironment Landscape?.
Kyriazi A, Karaglani M, Agelaki S, Baritaki S Cells. 2024; 13(15.
PMID: 39120310 PMC: 11312414. DOI: 10.3390/cells13151279.
Xu M, Hou Y, Li N, Yu W, Chen L J Transl Med. 2024; 22(1):418.
PMID: 38702756 PMC: 11067317. DOI: 10.1186/s12967-024-05169-9.
Biological biomarkers of oral cancer.
Radaic A, Kamarajan P, Cho A, Wang S, Hung G, Najarzadegan F Periodontol 2000. 2023; 96(1):250-280.
PMID: 38073011 PMC: 11163022. DOI: 10.1111/prd.12542.
Chu Y, Cheng L, Lim S, Lai M, Yeh C, Lin W Cell Death Dis. 2023; 14(10):660.
PMID: 37816733 PMC: 10564793. DOI: 10.1038/s41419-023-06187-z.
Alapati S, Fortuna G, Ramage G, Delaney C Metabolites. 2023; 13(8).
PMID: 37623834 PMC: 10456490. DOI: 10.3390/metabo13080890.